SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026. This represents a 79% increase from the 7,885 procedures recorded at the end of 2025. The installed base of SSi Mantra systems also expanded by 42%, rising to 238 systems from 168. These figures underscore the company's accelerating penetration in the global surgical robotics market, which could have profound implications for the accessibility of minimally invasive surgery.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the first installation of an SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's success in expanding its footprint across diverse healthcare environments.
Further evidence of the system's growing adoption comes from the 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries performed as of August 31. Notably, a telesurgery was conducted over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements demonstrate the platform's reliability and efficiency, which are critical for broader acceptance in both developed and emerging markets.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, the company believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones, if achieved, would open up two of the world's largest healthcare markets, potentially driving further procedure growth and revenue. For investors and industry observers, these developments signal a strengthening competitive position for SS Innovations in the surgical robotics sector.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company's product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For readers tracking healthcare innovation, the growth of SSi Mantra could signal a shift toward more cost-effective robotic surgery options, potentially increasing access in underserved regions. The company's progress with telesurgery also highlights the potential for remote surgical care, which could be transformative for patients in areas with limited access to specialized surgeons. To view the full report, visit https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
